Breaking News Instant updates and real-time market news.

AMGN

Amgen

$174.54

2.39 (1.39%)

, AGN

Allergan

$253.01

-1.15 (-0.45%)

09:02
07/31/17
07/31
09:02
07/31/17
09:02

Amgen and Allergan submit BLA to FDA for ABP 980

Amgen (AMGN) and Allergan (AGN) announced the submission of a Biologics License Application, or BLA, to the FDA for ABP 980, a biosimilar candidate to Herceptin. Amgen and Allergan are collaborating on four oncology biosimilar medicines, including ABP 980 which is the second to be submitted for FDA approval.

AMGN

Amgen

$174.54

2.39 (1.39%)

AGN

Allergan

$253.01

-1.15 (-0.45%)

  • 03

    Aug

  • 14

    Aug

  • 14

    Sep

  • 02

    Dec

  • 03

    Feb

  • 17

    May

AMGN Amgen
$174.54

2.39 (1.39%)

07/18/17
PIPR
07/18/17
NO CHANGE
Target $14
PIPR
Overweight
Piper says Array deal with Amgen 'another example' of successful partnering
Commenting on Array Biopharma's (ARRY) announcement of a preclinical autoimmune partnership deal with Amgen (AMGN), Piper Jaffray analyst Edward Tenthoff called the agreement "yet another example of Array successfully partnering its discoveries" and raising non-dilutive capital. Tenthoff keeps an Overweight rating and $14 price target on Array Biopharma shares.
07/26/17
BMOC
07/26/17
DOWNGRADE
BMOC
Market Perform
Amgen downgraded to Market Perform from Outperform at BMO Capital
07/26/17
OPCO
07/26/17
NO CHANGE
Target $203
OPCO
Outperform
Amgen price target raised to $203 from $189 at Oppenheimer
Oppenheimer analyst Leah Rush Cann raised her price target for Amgen to $203 from $189 after the company reported "strong" Q2 results. The analyst reiterates an Outperform rating on the shares.
07/26/17
BMOC
07/26/17
DOWNGRADE
BMOC
Market Perform
Amgen downgraded on valuation lack of near-term catalysts at BMO Capital
As noted earlier, BMO Capital downgraded Amgen to Market Perform from Outperform. Analyst M. Ian Somaiya downgraded the stock based on valuation and his belief that American College of Cardiology guidelines probably won't be updated until late 2018, likely preventing a positive turning point in Repatha sales until 2019. Target $199.
AGN Allergan
$253.01

-1.15 (-0.45%)

06/29/17
COWN
06/29/17
NO CHANGE
Target $400
COWN
Outperform
Allergan could emerge winner in migraine paradigm, says Cowen
Cowen analyst Ken Cacciatore believes Allergan's presence in the migraine space should continue to strengthen in the near-term via continued Botox growth and in the longer-term via oral CGRP's. He believes the introduction of injectable CGRP's could actually create managed care increased utilization of Botox. Cacciatore reiterated his Buy rating and $400 price target on Allergan shares.
07/06/17
BERN
07/06/17
NO CHANGE
BERN
Allergan Q2 aesthetics survey mixed, says Bernstein
Bernstein analyst Aaron (Ronny) Gal says a survey of 100 high volume U.S. aesthetic physicians. in late June showed that Allergan's U.S. toxin market is growing above average levels, as more younger women and men are using its products. Gal adds that the line filler market "continues to grow well with 6%-12% sequential growth," as "Juvederm is gaining share" and doing well with men and women under 30. However, the analyst adds that the growth of Allergan's Kybella treatment is "modest," with the treatment increasingly seen as a "niche" offering. But Zeltiq is growing 9% sequentially, he added. Gal keeps a $296 price target and an Outperform rating on Allergan.
07/20/17
FBCO
07/20/17
NO CHANGE
Target $286
FBCO
Outperform
Allergan price target raised to $286 from $274 at Credit Suisse
Credit Suisse analyst Vamil Divan raised his price target for Allergan to $286 from $274 ahead of Q2 results. The analyst believes that important product data releases and approvals could be the key driver of further upside for the rest of 2017 and into 2018, and continues to see underappreciated value in recently launched products and the pipeline. Divan reiterates an Outperform rating on the shares.
07/26/17
SBSH
07/26/17
NO CHANGE
Target $290
SBSH
Buy
Allergan price target raised to $290 from $270 at Citi
Citi analyst Liav Abraham raised her price target for Allergan shares to $290 ahead of the company's Q2 earnings report on August 3. The analyst is constructive on the shares, noting her revenue estimates are 1% ahead of the Street. She keeps a Buy rating on Allergan.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.